• Home/
  • News/
  • India To Have Five More COVID Vaccines By October, Sputnik V Expected To Get Emergency Use Nod In 10 Days

News

India To Have Five More COVID Vaccines By October, Sputnik V Expected To Get Emergency Use Nod In 10 Days

The five COVID-19 vaccines are Sputnik V vaccine (in collaboration with Dr. Reddy’s), Johnson & Johnson vaccine (in collaboration with Biological E), Novavax vaccine (in collaboration with Serum India), Zydus Cadila’s vaccine, and Bharat Biotech’s Intranasal Vaccine

India To Have Five More COVID Vaccines By October, Sputnik V Expected To Get Emergency Use Nod In 10 Days
Highlights
  • India currently has two COVID-19 vaccines: Covishield and Covaxin
  • India can expect five more vaccines by quarter 3 of 2021
  • COVID-19 vaccine Sputnik V is likely to get the emergency use license soon

New Delhi: As more and more states flag shortage of COVID-19 vaccine doses, the Central government has pressed the accelerator to scale up vaccine production manifold. Top government sources told ANI that by end of the third quarter of this year, India will be getting vaccines from five additional manufacturers. India currently manufactures Covishield and Covaxin. Explaining the new strategy to manufacture additional vaccine doses, a source said, “India currently has 2 COVID-19 vaccines being manufactured locally: Covishield and Covaxin, and we can expect five more vaccines by Q3 2021. These vaccines are Sputnik V vaccine (in collaboration with Dr. Reddy’s), Johnson & Johnson vaccine (in collaboration with Biological E), Novavax vaccine (in collaboration with Serum India), Zydus Cadila’s vaccine, and Bharat Biotech’s Intranasal Vaccine. Safety and efficacy are the Union government’s primary concerns while granting emergency use authorisation (EUA) to any COVID-19 vaccine in the country.”

Also Read: Benefits Of AstraZeneca’s COVID-19 Vaccine Outweigh Risks Despite ‘Possible Links’ Of Blood Clots, Says EU Regulator

Out of almost 20 COVID-19 vaccines in various clinical and pre-clinical stages, Sputnik V vaccine will get the nod first. It is expected that Sputnik is likely to get the EUA within the next ten days.

Russian Direct Investment Fund (RDIF) has tied up with a host of Indian pharmaceutical players such as Hyderabad based Dr Reddy’s Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech for the production of vaccine doses. With a production capacity of 850 million doses in the country, Sputnik V will provide a major shot in the arm in the fight against COVID-19.

Also Read: Indian Medical Association Urges PM Modi To Start Vaccination For All Above 18 Years, Suggests Limited Lockdown

When asked from a top-level source when will the vaccines be available for use, he said, “Sputnik is expected to be available latest by June, if all goes well Johnson and Johnson (Bio E) will be available by August, Cadilla Zydus will also be available by August, Novavax (Serum) by September and Nasal Vaccine (Bharat) by October.”

The Government is making all efforts to accelerate the progress without cutting any corners in research, development, and clinical trial stages, the source added. The government is taking all steps to augment vaccine production and availability in India. A decision has been taken at the highest level to ensure all steps are taken to help domestic manufacturers to scale up vaccine production manifold.

Also Read: On-Site COVID Vaccine Registrations For Health And Frontline Workers Only At Government Sites: Centre

The Government of India is determined to ensure India remains the pharmacy of the world and Indians have equitable access to the highest quality vaccines in the world. We encourage all COVID-19 vaccine manufacturers to come to India, as the Central Government is ready to provide manufacturing assistance, financial support, and partnership in running and designing clinical trials, sources added.

India is currently facing the second wave of COVID-19 pandemic with the number of new cases increasing each day.

Also Read: Dynamic Strategy Prioritising COVID-19 Vaccines For Seniors, Essential Workers Offers Greatest Public Health Benefit: Study

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

[corona_data_new]
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *